At VALDI Inc, in partnership with The Medical Research Group, we are engaged in a significant research study titled "Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)."
This study is a crucial step in advancing the understanding and treatment of Pulmonary Arterial Hypertension (PAH).
For a concise overview of the study and to gain in-depth insights, we encourage you to visit the following links:
-
View the study on ClinicalTrials.gov
-
Read more at Gossamer Bio
These resources provide valuable information for those interested in the latest developments in pulmonary health research. Stay informed and engaged with our ongoing efforts to improve the lives of those affected by PAH.
